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 72 
Abstract 73 
Context: Offspring exposed to maternal obesity in-utero are at an increased risk of later obesity; 74 
however the underlying mechanisms remain unknown.  75 
Objective: To assess the effect of an antenatal lifestyle intervention in obese women on the offspring’s 76 
cord blood metabolic profile, and determine association between the maternal clinical characteristics, 77 
cord blood metabolic profile and offspring body composition at birth and 6 months of age.  78 
Design: Randomised controlled trial and cohort study. 79 
Setting: Data from the UK Pregnancies Better Eating and Activity randomised controlled trial 80 
(UPBEAT). 81 
Participants: 344 mother-offspring pairs. 82 
Intervention: Antenatal behavioural lifestyle (diet and physical activity) intervention. 83 
Main outcome measures: Untargeted cord blood metabolic profile, including candidate hormone and 84 
metabolomic analyses. 85 
Results: The lifestyle intervention was not associated with change in any measures of the cord blood 86 
metabolic profile. Higher maternal glycaemia, specifically fasting glucose at 28 weeks’ gestation had 87 
a linear association with higher cord blood concentrations of lysophosphatidylcholines 16.1 (β=0.65; 88 
95%CI 0.03 to 0.10) and 18.1 (0.52; 0.02 to 0.80). A principal component of cord blood 89 
phosphatidylcholines and lysophosphatidylcholines was associated with infant z-scores of birthweight 90 
(0.04; 0.02 to 0.07) and weight at age 6 months (0.05; 0.00 to 0.10). Cord blood IGF-1 and 91 
adiponectin concentrations were also positively associated with infant weight z-scores at birth and at 6 92 
months.  93 
 Conclusions: We provide novel evidence that lysophosphatidylcholines and IGF-1 measured in cord 94 
blood are related to infant weight. These findings lend support to the hypothesis that susceptibility to 95 
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childhood obesity may be programmed in-utero, but further investigation is required to establish 96 
whether these associations are causally related.  97 
Introduction 98 
The increasing incidence of childhood obesity is a major public health concern. Recent global 99 
estimates from the WHO, suggest that 41 million children under the age of 5 years are overweight or 100 
obese (1). Observational cohort studies and experimental animal studies have strongly suggested that 101 
both the pre- and postnatal environments modulate developmental pathways that increase 102 
susceptibility to later obesity (2). Offspring exposed to maternal obesity, excessive gestational weight 103 
gain (GWG) and/or gestational diabetes (GDM) in-utero are at an increased risk of obesity and altered 104 
glucose metabolism throughout the life-course (2, 3). Exposure to maternal obesity in-utero is 105 
proposed to set the offspring on a trajectory of increased adiposity throughout life due to persistent 106 
changes in metabolic function (4).  107 
 108 
Metabolomics enables the investigation of low-molecular weight molecules such as intermediate 109 
metabolites and signalling molecules and can be used as a tool to provide insight in the systemic 110 
perturbations of an individual as a result of pathophysiological in-utero exposure (5). Investigations of 111 
cord blood metabolic profiles have previously been conducted within small cases-control studies 112 
assessing associations with birth weight or post-natal trajectories and with limited adjustment for in-113 
utero confounding variables. In a large birth cohort from Germany, certain cord blood metabolites 114 
were associated with birth weight (6). However, neonatal adiposity explains only 40% of the observed 115 
variation in birthweight.  116 
 117 
To date, no investigations have addressed the relations between maternal clinical and biochemical 118 
characteristics in obese women and fetal metabolism, in association with neonatal and early infancy 119 
weight and anthropometric measures of adiposity. We examined these relations in a group of obese 120 
pregnant women and their offspring who had taken part in the UK Pregnancies Better Eating and 121 
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Activity Trial (UPBEAT); a randomised controlled trial assessing a behavioural lifestyle intervention 122 
in 1555 obese pregnant women (7). Although the trial intervention did not reduce the incidence of 123 
GDM and delivery of a large for gestational age infant (primary outcomes), we have recently reported 124 
a reduction in infant subscapular skinfold thickness at 6 months of age mediated through significant 125 
improvements in maternal antenatal diet, measures of adiposity and GWG initiated by the UPBEAT 126 
intervention (8).  127 
 128 
Our primary aim was to determine if the intervention resulted in changes in an untargeted cord blood 129 
metabolic profile and candidate hormones previously implicated with obesity and fetal growth. The 130 
secondary aim was to explore the relations between maternal antenatal characteristics including total 131 
GWG, pre-pregnancy BMI and GDM and cord blood metabolic profile. As weight and adiposity have 132 
been shown to track through childhood, further assessment was made for potential relations between 133 
metabolites in the cord blood and measures of weight and anthropometry in offspring at birth and at 6 134 
months of age. 135 
 136 
 137 
  138 
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Subjects and Methods  139 
Study Design  140 
This study was a secondary analysis from the UPBEAT trial(7). To assess the primary aim of this 141 
study; the influence of the UPBEAT lifestyle intervention on the cord blood metabolic profile, the 142 
UPBEAT study was treated as an RCT (7). As the secondary aim of the study was to assess the 143 
relationship of the cord blood metabolic profile with maternal clinical characteristics and neonatal and 144 
infant anthropometry, an analysis based on a cohort study approach was chosen using both active 145 
treatment and control groups, and taking into account the original randomisation allocation.  146 
 147 
Study population  148 
Primary aim  149 
Women over the age of 16 years were recruited to the UPBEAT trial between 15+0-18+6 weeks’ 150 
gestation. The participants were from inner-city populations with high socioeconomic deprivation. 151 
The detailed study design including inclusion and exclusion has been previously published (7).  152 
In summary, the UPBEAT study recruited 1555 obese women from 8 tertiary maternity units located 153 
within inner city populations at 15+0-18+6 weeks’ gestation. A behavioural intervention was devised 154 
based on psychological models of health behaviour including control and social cognitive theory, 155 
delivered via weekly sessions to increase physical activity and reduce maternal glycaemic load and 156 
saturated fat intake. The primary maternal outcome was a reduction in the incidence of GDM at 27-157 
28+6 weeks gestation and the neonatal outcome was a reduction in the delivery of a large for 158 
gestational age infant. Women were randomised using an online database with minimisation for 159 
ethnicity, parity and BMI, to ensure that the groups were comparable at baseline. 47.3% of offspring 160 
were followed up at 6 months postpartum. In comparison to those who did not take part, the mothers 161 
were older, more likely to be White, nulliparous and less likely to be current smokers (See 162 
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Supplement, Table 2). There was no significant difference in sessions covered between those who did 163 
and did not take part in the present study (p=0.09). 164 
 165 
Secondary aim  166 
Mother-neonate pairs were included in the analyses if detailed neonatal anthropometric and cord 167 
blood metabolic data were available. Infants were included within the further analysis of data at 168 
6months of age if they attended that follow-up appointment and did not suffer from major ill health.  169 
 170 
Cord blood analyses  171 
Cord blood biomarkers  172 
Candidate cord blood biomarkers assessed in this study include cord blood insulin, C-peptide, 173 
glucose, LDL-c, HDL-c, triglycerides, adiponectin, leptin, IGF I, II, IL-6 and TNF-α (Supplement 174 
Text 1). 175 
 176 
Metabolomic analyses 177 
An untargeted cord plasma metabolome was analysed using mass spectroscopy, enabling the 178 
quantification of phospholipids, acylcarnitines, non-esterified fatty acids (NEFA), carboxylic acids 179 
and amino acids as described previously (Supplement Material Text 1) (9, 10). Analysis was 180 
undertaken in eight batches. 181 
 182 
Maternal variables  183 
Maternal clinical characteristics investigated, included maternal early pregnancy BMI (kg/m2); total 184 
GWG (kg) defined from pre-pregnancy to 34-36 weeks’ gestation; GDM defined using the IADPSG’s 185 
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diagnostic criteria at 24-28+6 weeks’ gestation, and the fasting glucose, 1 and 2 hour glucose 186 
concentrations at the time of the OGTT (11).  187 
 188 
Offspring anthropometry  189 
Neonate  190 
Anthropometric measurements were made within 72 hours of birth by a trained midwife. Birthweight 191 
was recorded from maternal medical records and birthweight z-scores calculated using a UK reference 192 
population taking into account adjusted for sex and gestation at delivery (12). Neonatal subscapular 193 
and triceps skin fold thicknesses (SFT) were measured using Harpenden skinfold callipers in triplicate 194 
and the sum of skin fold thickesses (SSFT) were calculated. Neonatal length was assessed using a 195 
neonatometer. Abdominal and mid upper arm circumferences were assessed. 196 
 197 
Infant 198 
Anthropometric measurements were collected at 6 months of age by a trained midwife. Weight was 199 
assessed using SECA® scales, and length assessed in the supine position using an infantometer. 200 
Triceps and subscapular SFT were measured in triplicate using Holtain callipers. Where reference 201 
WHO population data were available, z-scores were calculated, adjusting for infant sex and age at 202 
measurement (13). Early catch-up growth was defined using the WHO definition of catch up growth, 203 
defined as an increase ≥0.67SDs in weight-z-scores from birth to 6 months of age (13). Similarly 204 
catch down growth was defined as a decrease in weight-z-scores from birth to 6 months of age of 205 
≥0.67SDs (13).  206 
 207 
Statistical analyses  208 
Cord blood metabolic profile  209 
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To correct for potential batch effects with the cord blood metabolomics analysis, linear regression 210 
models were applied and the residuals were used for further statistical analysis. Metabolites were 211 
standardised to average metabolite concentrations and standard deviation over all eight batches for 212 
statistical analysis. Metabolites were included in the analyses if if they had > 70% complete data. 213 
Cord blood biomarkers and metabolomic variables were assessed for normality and transformed 214 
appropriately. Variables were summarised using mean (SD) and median (IQR) where appropriate.  215 
 216 
Principal component analysis was undertaken for the metabolomic data only, to reduce the number of 217 
metabolites based on a series of uncorrelated linear combinations of variables containing the most 218 
variance. Following orthogonal rotation, metabolites with a loading ≥0.1 were considered to have a 219 
strong association with the cluster.  220 
 221 
Effect of a lifestyle intervention on the cord blood metabolic profile  222 
Assessment was made for any differences in maternal characteristics and birth outcomes between 223 
those included vs. those excluded from the analysis. Adjustment was made for any apparent 224 
differences in maternal characteristics at trial entry (15+0-18+6 weeks’ gestation) between the two 225 
arms. The effect of the UPBEAT intervention was assessed using linear regression adjusting for 226 
minimisation variables used at trial randomisation (ethnicity, parity and maternal early pregnancy 227 
BMI). 228 
 229 
Maternal associations with cord blood metabolic profile  230 
Maternal antenatal variables (including early pregnancy BMI, GWG and GDM) were assessed in 231 
relation to the cord blood metabolic profile. To assess for potential relationships, multivariable linear 232 
regression was undertaken, where components of the cord blood metabolic profile were treated as the 233 
11 
 
outcome and maternal antenatal variables as the exposure adjusting for offspring sex, gestational age 234 
at delivery and randomisation to the UPBEAT intervention.  235 
 236 
Cord blood metabolic profile and offspring anthropometry 237 
To assess the association between the cord blood metabolic profile (exposure) and subsequent 238 
offspring anthropometry (outcome) at birth and at 6 months, multivariable linear or logistic regression 239 
was undertaken where appropriate. 240 
 241 
Adjustment was made for confounders, selected a-priori based on clinical knowledge with the aid of 242 
directed acyclic graphs (DAGs) (Supplement Text 2). Unless a systematic approach is taken, adjusting 243 
for potential confounders may increase bias. The proper use of DAGs in selecting covariates is likely 244 
to reduce the degree of bias (14). Selected confounders included age at anthropometric measurement, 245 
offspring sex where appropriate and randomisation to the UPBEAT intervention (Model 1). Further 246 
adjustment was made for maternal parity, ethnicity (reference white ethnicity), current smoker in early 247 
pregnancy, GDM, GWG (Model 2).  For potential associations of metabolic profile at birth and infant 248 
anthropometry at 6 months of age, further adjustment was made for mode of feeding (reference 249 
exclusive breastfeeding ≥4 months of age).  250 
 251 
All linear regression models were further assessed for data points exhibiting high leverage by using 252 
Cook’s Distance (defined as Di>4/n), heteroscedasticity and linearity. Correction for multiple testing 253 
was undertaken using a false discovery rate utilising the Benjamin & Hochberg procedure. Presented 254 
significance levels were corrected for multiple testing (statistical significance p<0.05) (15).  255 
 256 
Sensitivity analyses 257 
12 
 
Sensitivity analysis were undertaken by assessing demographic characteristics for those included 258 
within the analyses versus the mother-offspring pairs excluded. Sensitivity analyses were performed 259 
excluding offspring born <34 weeks’ gestation. A further sensitivity analyses was undertaken 260 
excluding mothers diagnosed with GDM. As mode of delivery has been shown to influence the cord 261 
blood metabolic profile, a fourth sensitivity analysis was undertaken with statistical models further 262 
adjusted for mode of delivery (reference category; unassisted vaginal delivery).  263 
 264 
All statistical analyses were performed using Stata Version 14.1.  265 
  266 
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Results  267 
Demography  268 
Of the 608 cord samples available from neonates born to women randomised to the UPBEAT trial, 269 
343 mother-offspring pairs were included (Supplement Figure 2). Median maternal BMI was 35.6 270 
kg/m2 (IQR 33.0, 38.9), 71.7% were of a white ethnic group and 87.8% were in the highest quintiles 271 
of socioeconomic deprivation. Median neonatal birthweight was 3.5 kg (IQR 3.21, 3.82 kg) and 272 
26.0% of offspring demonstrated significant catch-up growth as defined as >0.67 SD increase in 273 
infant weight z-scores between offspring birthweight and assessment at 6 months of age. Further 274 
maternal, neonatal and infant demographics and anthropometric characteristics are provided in Table 275 
1. To assess for potential selection bias, comparisons were made between mother-offspring pairs 276 
included and excluded from the analysis. The incidence of black ethnicity, neonatal birthweight and 277 
subscapular SFT were different between the two groups (Supplement Table 2). There was no 278 
difference in the incidence of GDM, total GWG or infant anthropometric measures between the two 279 
groups (Supplement Table 2).  280 
 281 
191 cord blood metabolites and 12 candidate biochemical markers were included in the analyses. 282 
Summary statistics of cord biochemical analyses including candidate biomarkers and metabolomic 283 
analyses are shown in Supplement Table 3. Following PCA, 4 distinct principal components of 284 
metabolites were identified which were; “Phosphatidylcholines”, “Non-esterified fatty acids”, “Long-285 
chain Acylcarnitines and TCA metabolites” and “Amino acids” (Supplement Figure 3a-d).  286 
 287 
Effect of the UPBEAT intervention  288 
Mother’s included in this analysis were older, more likely to be nulliparous and less likely to be of 289 
black ethnic origin compared to those without a cord blood sample (Supplement Table 4). Following 290 
correction for multiple testing, there were no significant differences in the cord blood metabolic 291 
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profile including clusters derived from PCA, between intervention and control arms (Supplement 292 
Figure 4).   293 
 294 
Relationships between maternal exposures and cord blood metabolic profile 295 
Diagnosis of maternal GDM was associated with reduced cord blood adiponectin and increased 296 
isocitric acid and lysophosphatidylcholine (LPC) 18.1 concentrations following correction for 297 
multiple testing by using a FDR (Supplement Figure 5). Both maternal early pregnancy BMI and total 298 
GWG were not associated with the cord blood metabolic profile (Supplement Figure 6 and 7). 299 
Maternal fasting glucose collected at the time of the OGTT (28 weeks’ gestation) was positively 300 
associated with higher cord insulin, C-peptide, LPC 18.1, 18.2 and 20.4, alpha aminoadipic acid and 301 
citric acid following correction for multiple testing. Maternal fasting glucose was also associated with 302 
lower cord adiponectin and NEFA 26.0 (Figure 1). Associations between maternal glucose at 1 hour 303 
and 2 hour post OGTT are illustrated in Supplement Figure 8 and 9.  304 
 305 
Cord blood metabolic profile and neonatal anthropometry  306 
There was a positive linear relationship between cord C-peptide, insulin, IGF-1, leptin and neonatal 307 
birthweight z-scores, SSFT, subscapular SFT, triceps SFT (except for insulin, and C-peptide), mid 308 
upper arm and abdominal circumference (Table 2, Supplement Figure 10). Principal components of 309 
NEFAs as assessed in the metabolome and cord blood triglycerides were inversely associated with 310 
neonatal birthweight z-scores, SSFT, subscapular SFT, triceps SFT and mid upper arm circumference 311 
at birth (Table 2, Supplement Figure 10). HDL, adiponectin and principal components of 312 
phosphatidylcholines were linearly associated with birthweight z-score only. LPC 16.1 and 18.0 were 313 
positively associated with neonatal birth weight, SSFT, subscapular and triceps SFTs following 314 
correction for multiple testing (Figure 2). Cord blood cholesterol was not associated with any measure 315 
of neonatal anthropometry (Supplement Figure 10). Interleukin-6 and TNF-α were negatively 316 
associated with neonatal birthweight z-scores. There were no associations between cord principal 317 
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components of acylcarnitines, amino acids and IGF-II with any measure of neonatal anthropometry 318 
(Table 2, Figure 2 and Supplement Figure 10). 319 
 320 
Cord blood metabolic profile and infant anthropometry at 6 months of age 321 
Of those biochemical variables,  which were significantly associated with neonatal body composition, 322 
clusters of phosphatidylcholines and adiponectin were linearly associated with infant weight and 323 
length z-scores at 6 months of age (Figure 2, Supplement Table 5). In particular, LPC 16.1 and 18.1 324 
were linearly associated with infant weight z-scores at 6 months of age (Figure 2, Supplement Table 325 
5). Cord IGF-I was linearly associated with infant weight z-scores, BMI z-score and mid upper arm 326 
circumference z-score (Figure 2, Supplement Table 5). Cord leptin and triglycerides were negatively 327 
associated with infant mid-upper arm circumference z-scores following adjustment for maternal and 328 
infant confounding (Figure 2, Supplement Table 5). There were no associations between cord insulin, 329 
glucose, C-peptide and IL-6 with infant anthropometry at 6 months of age (Figure 2, Supplement 330 
Table 5).  331 
 332 
For every unit increase in principal components of phosphatidylcholines, the odds of catch up growth 333 
at 6 months of age increased by 1.35 (1.04 to 1.75), whereas leptin decreased by 0.33 (0.17 to 0.52) 334 
(Supplement Table 6). IGF-1 and leptin were positively associated with increased odds of catch down 335 
growth at 6 months of age (Supplement Table 6).   336 
 337 
Sensitivity analyses 338 
The associations between cord blood metabolic profile and neonatal or infant body composition 339 
remained unchanged following removal of offspring born <34 weeks’ gestation (N=36) (Supplement 340 
Figure 11 & 12), those participants exposed to GDM (n=111) (Supplement Figure 13 & 14) and 341 
following further adjustment for mode of delivery (Supplement Figure 15 & 16).  342 
16 
 
Discussion  343 
This study reports a comprehensive cord blood metabolic profile, including candidate biochemical 344 
markers and metabolome, in offspring born to obese mothers. By demonstrating associations with 345 
fasting glucose, it has been shown that in-utero exposure to maternal dysglycaemia in obese 346 
pregnancies has the potential to modify the cord blood metabolic profile at birth. Although there was 347 
no effect of the UPBEAT antenatal lifestyle intervention on the cord blood metabolic profile, when 348 
treating the data as a cohort, associations were observed between the cord blood metabolic profile and 349 
offspring growth in early life. The novel associations between cord lysophosphatidylcholines and 350 
neonatal adiposity, together with the relation with maternal hyperglycaemia may provide mechanistic 351 
insight into the early-life origins of obesity.   352 
The lack of effect of the UPBEAT intervention on the cord metabolic profile may suggest that the 353 
differences observed in the maternal secondary outcomes including reduction in adiposity and 354 
gestational weight gain were inadequate to have a major impact on fetal metabolism, although more 355 
subtle molecular effects could have occurred to influence adiposity in the six month infants as 356 
recently reported (8). Principal components of phosphatidylcholines and lysophosphatidylcholines 357 
were found to be positively associated with early growth velocities and weight z-scores, providing 358 
possible mechanistic insight of the mechanisms contributing to early postnatal growth in offspring 359 
born to obese women. The finding that principal components of cord lysophosphatidylcholines, 360 
primarily lysophosphatidylcholines 16.1 and lysophosphatidylcholines 18.1 were not only associated 361 
with neonatal weight-z-scores, but also infant growth and catch-up growth within the first 6 months of 362 
age provides novel evidence, suggesting a role in the early life growth velocities. Of relevance, 363 
associations with cord lysophosphatidylcholines and birthweight were recently reported in a birth 364 
cohort from Germany(16). In the present study lysophosphatidylcholines were associated with 365 
neonatal adiposity as well as birthweight; supporting a role in body fat accretion. It may be of 366 
relevance to these observations that the infant growth trajectory in the first 6 months of life has been 367 
shown to be predictive of adolescence and early adulthood obesity (17) and that The European 368 
Childhood Obesity Programme has shown that lysophosphatidylcholines 14.0 correlate with rapid 369 
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growth in infancy and subsequent obesity at 6 years of age (16). Together these findings would 370 
suggest a possible role for lysophosphatidylcholines in the early life ‘programming’ of obesity risk 371 
(18).  372 
 373 
Further interrogation of the dataset demonstrated a significant linear relationship between cord blood 374 
insulin, C-peptide and IGF-1 with cord lysophosphatidylcholines (Supplement Figure 17 &18) 375 
supporting the suggestion of an interaction between fetal glucose homeostasis and these 376 
molecules(19). This observation is in part supported by one small case-control study (n=46) that 377 
identified an inverse relationship between maternal gestational diabetes and placental uptake of 378 
lysophosphatidylcholines 22:6, in women of heterogeneous BMI (20). A role in fetal metabolism for 379 
lysophosphatidylcholines has also been suggested in the non-pregnant state with the development of 380 
visceral fat obesity, unrelated to genetic origin but associated with nutritional status (21). A study 381 
from the USA Project Viva cohort, demonstrated that associations between cord blood metabolites 382 
from a  metabolome, particularly those related to one-carbon metabolism may contribute to rapid 383 
postnatal weight gain in offspring born to women of heterogeneous BMI (22). Taken together, studies 384 
of the cord blood metabolic profile suggest that obesity risk may be determined at birth (4). Antenatal 385 
interventions directed towards optimising adverse fetal exposures may therefore contribute to curbing 386 
the incidence of childhood obesity.  387 
 388 
The positive associations between cord blood IGF-1 with neonatal measures of growth and body 389 
composition together with infant weight and mid upper arm circumference z-scores at 6 months also 390 
suggests a persistent influence of in-utero exposures on early growth. Whilst the relationship between 391 
the cord blood metabolic profile and differential growth in early infancy suggests a potential 392 
persistent effect on growth at 6 months of age, mechanisms must remain conjectural and causal 393 
inference should be made with caution.  However, several studies have suggested that the IGF-1 gene 394 
may be prone to epigenetic modification in-utero (23-25), with animal studies shedding some light on 395 
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this in providing evidence of an interaction with maternal glycaemia status. For example, Zinkhan et 396 
al, demonstrated that in-utero exposure to maternal glycaemia in rats led to decreased hepatic 397 
H3Me3K36 and mRNA variants of the IGF-1 gene in the offspring (26). Others have implicated a role 398 
of these variants to a predisposition to later obesity and insulin resistance (25). Whether epigenetic 399 
modification may also influence lipid metabolism, including that of lysophosphatidylcholines, 400 
remains conjectural.  401 
 402 
The linear associations with cord adiponectin and measures of weight, length and subscapular z-403 
scores at 6 months are in keeping with recent evidence from a prospective cohort study from 404 
Germany, in children born to women of heterogeneous BMI (n=141); suggesting a potential long term 405 
influence in children at 5 years of age (27). We also found that cord blood leptin was associated with 406 
measures of neonatal growth and body composition and increased odds of catch up growth from birth 407 
to 6 months of age, suggesting a potential mediatory role of early infancy growth. Cord blood leptin 408 
has been implicated as a proxy for neonatal fat mass as it is synthesised by the adipocyte Ob gene and 409 
is proportional to adipose tissue mass (28). This study has demonstrated an inverse relationship with 410 
cord leptin and catch up growth independent of birthweight which may be explainable by a state of 411 
leptin resistance in early infancy, as observed in previous studies (29). 412 
 413 
The linear associations between cord blood anabolic hormones including cord blood C-peptide, 414 
insulin and IGF-1 with measures of growth and body composition at birth, agree with previous studies 415 
in offspring born to women of heterogeneous BMI (30, 31) and concur with the knowledge that 416 
insulin and IGF-1 are the most important regulators of fetal growth in the 2nd and 3rd trimester (32). 417 
IGF-1 has been shown consistently to be raised in cord blood of offspring born to obese women, 418 
predominately as a consequence of maternal dysglycaemia (33).  419 
 420 
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Triglycerides and non-esterified fatty acids in the maternal circulation have been widely implicated as 421 
determinants of fetal growth in obese and diabetic women (32). However, in this study, an inverse 422 
relationship between clusters of non-esterified fatty acids and triglycerides with neonatal growth and 423 
adiposity was observed, which has also been reported by others(34, 35). This association with low 424 
rather than high birth weight could reflect mobilisation of lipids as an alternative fuel source (34). 425 
Importantly, this study adds to others that have questioned the role of triglycerides in the 426 
determination of neonatal adiposity.  427 
 428 
Despite the suggestion that inflammatory mediators (interleukin-6 and tumour necrosis factor-α) may 429 
contribute to the development of neonatal adiposity in-utero, through regulation of central pathways 430 
of satiety and appetite, (36, 37). We  have found an inverse association with neonatal body 431 
composition. There is no obvious explanation for this observation. 432 
 433 
Strengths of this study include an extensive assessment of the cord blood metabolic profile at birth, 434 
detailed neonatal and infant anthropometric data collection and prospective collection of maternal 435 
early pregnancy BMI, total gestational weight gain and measures of maternal insulin resistance. Using 436 
data reduction techniques for the cord blood metabolome, metabolite clusters of biological importance 437 
associated with measures of neonatal and infant anthropometry were identified.  438 
 439 
Limitations include the collection of mixed cord blood (umbilical artery and vein), which weakens 440 
conclusions regarding fetal or maternal origin of the metabolites in this study, as well as previously 441 
published reports (22). Whilst treatment of GDM has the potential to influence cord insulin, C-peptide 442 
and IGF-1 concentrations, this was not adjusted for within this analysis, however a sensitivity 443 
analyses removing women with GDM did not modify the observed relationships. It must be 444 
recognised that the metabolome and the candidate markers measured provide only an incomplete 445 
profile of the late pregnancy in-utero fetal exposures as unmeasured micronutrients, essential fatty 446 
20 
 
acids and steroid hormones may also contribute to neonatal and early life growth and body 447 
composition.  448 
 449 
In summary, this study of more than 300 infants describes for the first time a comprehensive cord 450 
blood metabolic profile in offspring born to obese women. Known associations of metabolic variables 451 
with infant adiposity were confirmed and questions raised regarding previous associations derived 452 
from smaller cohorts. Importantly we have highlighted novel associations with lipid sub-species and 453 
early postnatal growth, and provide supporting evidence that IGF-1 at birth may be a determinant of 454 
later growth trajectories. Current investigation of the maternal metabolome and neonatal epigenome 455 
may shed light on the causative mechanisms and further insight into growth trajectories. Ongoing 456 
studies of the cord epigenome may provide further mechanistic insight into potential pathways. 457 
Replication in other cohorts including the use of Mendelian randomisation methods are required to 458 
determine causality. Ongoing follow-up of the UPBEAT offspring will address the long-term 459 
implications of these observed associations.  460 
 461 
  462 
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 Intervention  Control  All   
N Mean (SD)/ 
Median 
(IQR)/ 
N(%) 
N Mean (SD)/ 
Median 
(IQR)/ 
N(%) 
N Mean (SD)/ 
Median (IQR)/ 
N(%) 
Maternal      
Age (years) 169 31.0 (28.0, 
35.0) 
174 31.0 (27.0, 
35.0) 
343 31.0 (27.0, 35.0) 
BMI (kg/m2) 169 35.5 (33.0, 
39.1) 
174 35.7 (33.0, 
38.5) 
343 35.6 (33.0, 38.9) 
Ethnicity 
Asian  
169 
12 (7.1) 
174 
7 (4.0) 343 19 (5.5) 
Black  32 (18.9) 31 (17.8)  63 (18.4) 
Other  7 (4.1) 8 (4.6)  15 (4.4) 
White  118 (69.8) 128 (73.6)  246 (71.7) 
Multiparous 169 86 (50.9) 174  79 (45.4) 343 165 (48.1) 
Smoker in early pregnancy 169 7 (4.1) 174 12 (6.9) 343 19 (5.5) 
Socioeconomic deprivation  169 145 (85.7) 174 151 (86.8) 343 295 (87.8) 
Gestational weight gain (kg) 169 6.94 (4.27) 174 8.00 (3.79) 343 7.78 (4.07) 
Gestational diabetes  169 59 (34.9) 174 52 (29.9) 343 111 (32.4) 
Neonate     
Mode of 
delivery 
Vaginal 
169 
73 (43.2) 
174 
65 (37.4) 343 138 (40.2) 
Operative 
vaginal  
25 (14.8) 19 (10.9)  44 (12.8) 
Emergency 
C-section   
28 (16.6) 50 (28.7)  78 (22.7) 
Elective C-
section 
43 (25.4) 40 (23.0)  83 (24.2) 
Gestation at delivery (weeks) 169 39.7 (38.7, 
40.7) 
174 40.0 (38.7, 
41.0) 
343 39.9 (38.7, 40.9) 
Birthweight (kg) 169 3.51 (3.22, 
3.79) 
174  3.59 (3.19, 
3.86) 
343  3.6 (3.2, 3.8) 
Birthweight z scores  169  0.12 (0.99) 174 0.13 (0.99) 343 0.21 (0.76) 
Skinfold thickness-
subscapular (mm) 
169 5.81 (1.46) 174 5.75 (1.37) 343 5.78 (1.42) 
Skinfold thickness triceps 
(mm) 
169 5.33 (1.42) 174 5.34 (1.49) 343 5.34 (1.45) 
Sum of skinfold thicknesses 
(mm) 
169 11.14 (2.61) 174 11.09 (2.58) 343 11.12 (2.59) 
Midarm circumference (cm)  169 11.57 (0.98) 174 11.59 (0.97) 343 11.58 (0.97) 
Abdominal circumference 
(cm) 
169 32.71 (2.11) 174 32.57 (1.99) 343 32.63 (2.05) 
Infant      
Weight for age z-score  125 0.17 (1.04) 123 0.42 (0.97) 247 0.29 (1.01) 
Length for age z-score 120  0.36 (1.71) 119 0.54 (1.99) 238 0.44 (1.85) 
BMI for age z-score  120 -0.00 (1.62) 119 0.21 (2.02) 238 0.10 (1.84) 
Arm circumference z-score  125 1.11 (0.92) 122 1.40 (1.86) 246 1.25 (1.47) 
Triceps skinfold thickness z-
score 
124 0.17 (1.59) 119  0.44 (1.42) 242 0.29 (1.51) 
Subscapular skinfold 
thickness  z-score 
107 0.23 (1.42) 103 0.37 (1.49) 209 0.30 (1.45) 
Catch up growth*  125 31 (24.8) 122 34 (27.9) 246 64 (26.0) 
Catch down growth**  125 36 (28.8) 122 24 (19.7) 246 60 (24.4) 
 
Table  1: Maternal, neonatal and infant demographic, anthropometry and clinical 
characteristics of mother-offspring pairs by randomisation allocationincluded (n=343). 
Abbreviations BMI-Body Mass Index. *Catch up growth defined as a ≥ 0.67 SDs increase in weight-z-scores from birth to 6 
months of age. **Catch down growth defined as a ≥0.67 SDS decrease in weight-z-scores from birth to 6 months of age.
 Figure 1: VolcanoManhattan plots demonstrating the association of maternal fasting glucose at the time of the oral glucose tolerance test with the 
cord blood metabolic profile from infants born to obese pregnant women (n=607).  
Parameter estimates are graphically represented for each biochemical variable in relation to maternal clinical characteristics following adjustment using a false discovery rate (Benjamin & 
Hochberg procedure) (17). Statistical significance p<0.0027. Abbreviations; CARN-Carnitines;  HDL-High density lipoprotein; IGFI- Insulin growth factor I; IGF II- Insulin growth factor II; 
IL6- Interleukin 6; LPC- lysophosphatidylcholines; LPCE- lysophosphatidylethanolamine; PC-phosphatidylcholines; PCA- diacylphosphatidylcholines; PCE- acylalkylphosphatidylcholines; 
SM- sphingomyelins. TNFalpha- Tumor necrosis factor; X30B- x3methyl2oxobutanoicacid; X30V-- x4methyl2oxovalvericacid. NEFAs are described using the nomenclature CX:Y, where X is 
the length of the carbon chain, Y is the number of double bonds, OH in the formula means the molecule contains a hydroxyl-group. 
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Parameter Estimate Late 2nd trimester fasting glucose
Fasting glucose
Maternal Characteristics
 Birthweight z-scores 
(SDS)  
SSFT (mm) Subscapular SFT 
(mm) 
Triceps SFT (mm) MUAC (cm) Abdominal 
circumference (cm) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
PCA-
Phosphatidylcholines 
0.04 (0.02 to 0.07)** -0.11 (-0.25 to 0.03) -0.06 (-0.12 to 0.01) -0.05 (-0.15 to 0.04) 0.03 (-0.02 to 0.07) 0.01 (-0.10 to 0.11) 
PCA- NEFA -0.04 (-0.08 to 0.00)* -0.28 (-0.49 to -0.08)* -0.11 (-0.21 to 0.00)* -0.18 (-0.32 to -
0.03)* 
0.02 (-0.05 to 0.10) -0.01 (-0.17 to 0.15) 
PCA- Long chain 
acylcatnitines and TCA 
metabolites 
0.00 (-0.04 to 0.04) -0.05 (-0.27 to 0.17) -0.02 (-0.13 to 0.09) -0.03 (-0.18 to 0.12) -0.01 (-0.08 to 0.07) 0.01 (-0.15 to 0.17) 
PCA-Amino acids  0.05 (0.00 to 0.11) -0.05 (-0.36 to 0.25) 0.06 (-0.09 to 0.20) -0.11 (-0.32 to 0.10) 0.06 (-0.04 to 0.16) 0.19 (-0.03 to 0.40) 
Cpeptide (log2) ng/ml 0.27 (0.14 to 0.39)** 0.86 (0.22 to 1.50)* 0.52 (0.17 to 0.87)* 0.34 (-0.02 to 0.69) 0.25 (0.00 to 0.49)* 0.73 (0.22 to 1.25)* 
Insulin (log2) U/ml 0.16 (0.09 to 0.23)** 0.47 (0.12 to 0.82)* 0.31 (0.11 to 0.50)* 0.17 (-0.03 to 0.37) 0.16 (0.02 to 0.29)* 0.38 (0.10 to 0.67)* 
Glucose (log2) mmol/l -1.80 (-3.59 to 0.00)* -2.94 (-12.96 to 7.08) -3.68 (-9.32 to 1.96) 0.48 (-4.94 to 5.90) -2.13 (-6.01 to 1.75) -6.19 (-14.48 to 2.09) 
Triglycerides mmol/l -0.47 (-0.74 to -0.20)** -1.65 (-3.18 to -0.11)* -0.95 (-1.82 to -0.08)* -0.73 (-1.56 to 0.10) -0.90 (-1.48 to -0.33)* -1.05 (-2.32 to 0.22) 
Cholesterol mmol/l 0.13 (-0.06 to 0.32) -0.75 (-1.68 to 0.17) -0.45 (-0.97 to 0.07) -0.31 (-0.81 to 0.19) -0.11 (-0.48 to 0.25) 0.40 (-0.38 to 1.17) 
HDL mmol/l 0.22 (0.06 to 0.38)* -0.11 (-0.89 to 0.67) -0.25 (-0.68 to 0.17) 0.16 (-0.28 to 0.60) 0.02 (-0.27 to 0.32) 0.38 (-0.25 to 1.01) 
IGFI (log2) ng/ml 1.13 (0.97 to 1.29)** 1.80 (0.89 to 2.72)** 1.08 (0.58 to 1.59)** 0.72 (0.20 to 1.24)* 1.19 (0.87 to 1.51)** 2.41 (1.70 to 3.12)** 
IGFII (log2) ng/ml 0.31 (-0.02 to 0.65) 1.57 (-0.15 to 3.29) 0.68 (-0.27 to 1.63) 0.89 (-0.08 to 1.85) 0.29 (-0.37 to 0.96) 0.54 (-0.86 to 1.93) 
Leptin (log2) ng/ml 0.38 (0.30 to 0.46)** 1.59 (1.21 to 1.97)** 0.83 (0.62 to 1.04)** 0.76 (0.54 to 0.98)** 0.50 (0.35 to 0.66)** 0.80 (0.47 to 1.13)** 
Adiponectin (log2) ug/ml 0.40 (0.12 to 0.68) 0.64 (-0.79 to 2.08) 0.48 (-0.31 to 1.27) 0.07 (-0.73 to 0.87) 0.84 (0.31 to 1.37)* 1.16 (0.00 to 2.31)* 
IL6 (log2) pg/ml -0.04 (-0.07 to 0.00)* 0.06 (-0.11 to 0.23) -0.02 (-0.11 to 0.08) 0.08 (-0.02 to 0.17) -0.04 (-0.11 to 0.03) -0.14 (-0.28 to 0.00)* 
TNF alpha (log2) pg/ml -0.58 (-1.12 to -0.03)* -1.44 (-4.21 to 1.32) -0.72 (-2.25 to 0.80) -0.86 (-2.41 to 0.69) -0.84 (-1.87 to 0.19) -0.61 (-2.82 to 1.60) 
 
Table 2: Associations of the cord blood metabolic profile with neonatal anthropomety in infants born to obese pregnant women (n=344) 
Regression coefficients with corresponding 95% confidence intervals presented are adjusted for maternal parity, ethnicity, smoker in early pregnancy, gestational diabetes, gestational weight 
gain, offspring sex, gestation at delivery, randomisation to UPBEAT Intervention. Abbreviations; HDL- High density lipoprotein; IGFI- Insulin growth factor I; IGFII- Insulin growth factor II; 
IL6-Interleukin 6; MUAC-Mid upper arm circumference; NEFA- Non-esterified fatty acids;  SDS- Standard deviation scores; SFT- skinfold thickness; TCA- Tricarboxylic acid; TNFalpha- 
Tumour Necrosis Factor alpha.  *p<0.05; ** p<0.001.  
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Figure 2: Heat map demonstrating associations between cord blood metabolites with anthropometric measurements in neonates (n=344) and six 
month old infants (n=209). Data from infants born to obese pregnant women in the UPBEAT study. 
Regression coefficients plots with adjustment made for maternal parity, ethnicity, smoker in early pregnancy, gestational diabetes, gestational weight gain, offspring sex, gestation at delivery, 
randomisation to UPBEAT Intervention. Additional adjustment is made for early mode of infant feeding for infant anthropometry data at 6 months of age. Abbreviations; BW- Neonatal 
birthweight z-scores (SDs); CARN-Carnitines; LPC- lysophosphatidylcholines; LPCE- lysophosphatidylethanolamine; MUAC- Mid upper arm circumference (cm); PC-phosphatidylcholines; 
PCA- diacylphosphatidylcholines; PCE- acylalkylphosphatidylcholines SM- sphingomyelins; SSF- Sum of skinfold thicknesses (mm); Tri SFT- Triceps skinfold thickness (mm); Sub SFT- 
Subscapular skinfold thickness (mm); X30B- 3methyl2oxobutanoicacid; X30V- 3methyl2oxovalvericacid; X40B- x4methyl2oxovalvericacid. NEFAs are described using the nomenclature CX:Y, 
where X is the length of the carbon chain, Y is the number of double bonds, OH in the formula means the molecule contains a hydroxyl-group.  
 
